GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (OTCPK:INNMF) » Definitions » Scaled Net Operating Assets

INNMF (Amplia Therapeutics) Scaled Net Operating Assets : 0.58 (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Amplia Therapeutics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Amplia Therapeutics's operating assets for the quarter that ended in Sep. 2024 was $6.53 Mil. Amplia Therapeutics's operating liabilities for the quarter that ended in Sep. 2024 was $0.93 Mil. Amplia Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $9.73 Mil. Therefore, Amplia Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was 0.58.


Amplia Therapeutics Scaled Net Operating Assets Historical Data

The historical data trend for Amplia Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics Scaled Net Operating Assets Chart

Amplia Therapeutics Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.72 1.16 0.82 0.33 0.51

Amplia Therapeutics Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 0.41 0.58 0.56 0.58

Competitive Comparison of Amplia Therapeutics's Scaled Net Operating Assets

For the Biotechnology subindustry, Amplia Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amplia Therapeutics's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's Scaled Net Operating Assets falls into.



Amplia Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Amplia Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Mar. 2024 )
=(Operating Assets (A: Mar. 2024 )-Operating Liabilities (A: Mar. 2024 ))/Total Assets (A: Mar. 2023 )
=(7.514-1.207)/12.473
=0.51

where

Operating Assets(A: Mar. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=9.734 - 2.22
=7.514

Operating Liabilities(A: Mar. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=2.247 - 0.009 - 1.031
=1.207

Amplia Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2024 )
=(Operating Assets (Q: Sep. 2024 )-Operating Liabilities (Q: Sep. 2024 ))/Total Assets (Q: Mar. 2024 )
=(6.53-0.931)/9.734
=0.58

where

Operating Assets(Q: Sep. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=9.616 - 3.086
=6.53

Operating Liabilities(Q: Sep. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=0.968 - 0 - 0.037
=0.931

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amplia Therapeutics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Amplia Therapeutics Business Description

Traded in Other Exchanges
Address
350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.